Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Carlsmed (CARL) Common Equity (2024 - 2025)

Carlsmed's Common Equity history spans 2 years, with the latest figure at $98.9 million for Q4 2025.

  • For Q4 2025, Common Equity rose 239.98% year-over-year to $98.9 million; the TTM value through Dec 2025 reached $98.9 million, up 239.98%, while the annual FY2025 figure was $98.9 million, 239.98% up from the prior year.
  • Common Equity reached $98.9 million in Q4 2025 per CARL's latest filing, down from $106.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $106.7 million in Q3 2025 to a low of -$83.1 million in Q2 2025.